Viatris (VTRS) grabbed the spotlight after posting third quarter revenues that came in ahead of expectations and raising its guidance for both full-year revenue and adjusted EBITDA. See our latest ...

Viatris is down 40% since the spin-off. Financial metrics are positively increasing as one-time costs of the merger are decreasing. Safe and high dividend yield combined with exceptional free cash ...

Good morning, everyone, and welcome to the Viatris Q3 2024 Earnings Call. All participants will be in a listen-only mode. [Operator Instructions] After today's presentation, there will be an ...

Viatris is leaving the biosimilar field just months after winning the landmark FDA approval for the first interchangeable biosimilar product. Biocon Biologics, a subsidiary of Biocon, will buy Viatris ...

As Viatris looks to shed its reputation as a company focused solely on generics and reach $1 billion in eye care sales, the drugmaker has laid out a near-term goal to close three divestitures. Viatris ...

Viatris, Inc. is a global healthcare company, which engages in the provision of healthcare and pharmaceutical products. It provides medicines and treatments in various therapeutic areas such as ...

Viatris continues to execute on its 2025 strategic priorities, including driving commercial execution, advancing its pipeline, prioritizing capital return with a focus on share repurchases, targeting ...

Viatris has a history of addressing public health challenges, including those related to opioids. The company manufactures generic versions of naloxone, an overdose reversal drug, and ...

Vanda Pharmaceuticals said on Tuesday its drug for the prevention of motion-induced vomiting was approved by the U.S. health regulator, becoming the first treatment for the condition to receive the ...